Get the Stockscreener App
5.13
10.55%
-0.605
After Hours:
5.20
0.07
+1.36%
Evoke Pharma Inc stock is traded at $5.13, with a volume of 237.33K.
It is down -10.55% in the last 24 hours and up +77.35% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$5.735
Open:
$5.35
24h Volume:
237.33K
Relative Volume:
0.11
Market Cap:
$7.66M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.4651
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
+92.86%
1M Performance:
+77.35%
6M Performance:
+13.75%
1Y Performance:
-27.54%
1-Day Range:
$4.9001
$5.59
1-Week Range:
$4.9001
$9.88
52-Week Range:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
5.13 | 3.97M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
152.86 | 70.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.75 | 47.44B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.73 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.04 | 19.07B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.24 | 13.28B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
How Evoke Pharma Inc. stock performs during market volatilityFree Real-Time Stock Data - Newser
What makes Evoke Pharma Inc. stock price move sharplyProven High Yield Signals - Newser
Small Cap Stocks Worth Watching – July 9th - Defense World
Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - Asianet Newsable
Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest
Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener
Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade
EVOK Stock: Boom or Bust? - timothysykes.com
Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus
Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com Nigeria
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com
Evoke Pharma (EVOK) Secures Key Patent for Gastroparesis Treatment | EVOK Stock News - GuruFocus
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | EVOK Stock News - GuruFocus
Evoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in Treatment of Gastroparesis Symptoms - Quiver Quantitative
Evoke Pharma Receives Notice of Allowance for U.S. Patent - GlobeNewswire
Major Patent Win: GIMOTI Locks Down 6 More Years of Exclusivity for Revolutionary Gastroparesis Spray - Stock Titan
Evoke Pharma Secures Patent for GIMOTI Treatment - TipRanks
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Evoke Pharma (NASDAQ:EVOK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance
Gastroparesis Treatment Market Booming Worldwide with - openPR.com
Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com
Geriatric Medicines Market Expands Globally with Aging - openPR.com
Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com
Global Geriatric Medicines Market Generated Opportunities, - openPR.com
Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com
Evoke Pharma Holds Annual Meeting via Webcast - TipRanks
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World
Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):